{
    "2018-08-30": [
        [
            {
                "time": "2018-09-14",
                "original_text": "CRON Goes Up In Smoke On Citron Report, Hot AFMD Is Cooling Now, REPL On Watch",
                "features": {
                    "keywords": [
                        "CRON",
                        "Citron Report",
                        "AFMD",
                        "REPL"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "U.S. Stocks Snap Four-Day Win Streak on Renewed China Trade Concerns",
                "features": {
                    "keywords": [
                        "U.S. Stocks",
                        "China Trade",
                        "Concerns"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "global trade",
                        "economy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer’s Quarterly Revenues and Estimates for 2018",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Quarterly Revenues",
                        "Estimates",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer’s Developments in August",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Developments",
                        "August"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Earnings",
                        "Stock Performance"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer’s Stock Performance in August",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock Performance",
                        "August"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication",
                "features": {
                    "keywords": [
                        "Scholar Rock",
                        "Pfizer",
                        "Discontinues",
                        "Medication"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Dow Movers: DWDP, PFE",
                "features": {
                    "keywords": [
                        "Dow",
                        "Movers",
                        "DWDP",
                        "PFE"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "industrial",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Blincyto",
                        "EU Nod",
                        "Pediatric Use"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
                "features": {
                    "keywords": [
                        "First Trust",
                        "Capital Strength ETF",
                        "Investing Radar"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Therapy",
                        "Duchenne Muscular Dystrophy"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "rare diseases"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Pfizer Inc."
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "analysis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Domagrozumab",
                        "Clinical Studies",
                        "Duchenne Muscular Dystrophy"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "clinical trials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "3 High-Yield Healthcare Dividend Stocks Still Worth Buying",
                "features": {
                    "keywords": [
                        "High-Yield",
                        "Healthcare",
                        "Dividend Stocks"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer Terminates Two Duchenne Muscular Dystrophy Studies",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Terminates",
                        "Duchenne Muscular Dystrophy",
                        "Studies"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "rare diseases"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}